Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com
Acalabrutinib With/Without Obinutuzumab Is Effective in Higher-Risk Chronic Lymphocytic Leukemia
Acalabrutinib-containing regimens demonstrated long-term efficacy with a tolerable safety profile in higher-risk chronic lymphocytic leukemia.
Read More
Pirtobrutinib Displays Efficacy in Patients With Richter Transformation
Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.
ASCO Issues Statement Calling for Streamlined Clinical Trial Requirements
ASCO has released a research statement outlining 4 recommendations to decentralize clinical trials and improve patient access to these studies.
T-DXd Wins Conditional Approval in China for Pretreated HER2+ Gastric/GEJ Cancer
Trastuzumab deruxtecan earned conditional approval in China for HER2-positive gastric/gastroesophageal junction cancer after at least 2 lines of therapy.
Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC
Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.
Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia
Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.
RLY-2608 Uses PI3Kα Mutant–Specific Inhibition to More Safely Treat Breast Cancer and Other Solid Tumors
Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.
Orelabrutinib Plus Lenalidomide and Rituximab Demonstrates Efficacy in Frontline MCL
Orelabrutinib in combination with lenalidomide and rituximab was safe and active in treatment-naive mantle cell lymphoma.
Guardant Reveal Test Is Effective in Predicting Recurrence in Stage II and Higher CRC
The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.
Serial Clinical Response Evaluation Aids in Residual Disease Detection in ESCC
Bite-on-bite biopsies and endoscopic ultrasonography with fine needle aspiration were accurate in detecting MRD after neoadjuvant chemoradiotherapy in ESCC.
Ibrutinib Plus Lenalidomide and Rituximab Demonstrates Activity in R/R MCL
The combination of ibrutinib, lenalidomide, and rituximab elicited a high response rate in patients with relapsed/refractory mantle cell lymphoma.
Selpercatinib Maintains PFS Benefit vs Chemotherapy in East Asian Patients With Untreated RET+ NSCLC
East Asian patients with RET fusion-positive NSCLC experienced a PFS benefit when treated with selpercatinib vs chemotherapy with/without pembrolizumab.
PGDx Elio Plasma Focus Dx Receives FDA De Novo Marketing Authorization for Pan–Solid Tumor Liquid Biopsy
The FDA has granted de novo marketing authorization to the PGDx elio plasma focus Dx pan–solid tumor liquid biopsy test.
Alemtuzumab Earns FDA Orphan Drug Designation for Lymphodepletion Before UCART22 in R/R B-ALL
Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.
Minimal Residual Disease Status Displays Association with PFS in CLL
Minimal residual disease status was associated with progression-free survival in chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.
NCCN Recommends Imetelstat for Symptomatic Anemia in Lower-Risk MDS
The National Comprehensive Cancer Network has issued category 1 and 2A recommendations for imetelstat as therapy for symptomatic anemia in patients with lower-risk MDS.
BNT111 Plus Cemiplimab Generates Responses in Unresectable Stage III/IV Melanoma
The addition of BNT111 to cemiplimab has produced clinical activity in anti-PD-(L)1 relapsed/refractory unresectable stage III or IV melanoma.
Shield Blood Test Receives FDA Approval for CRC Screening in Adults
The Shield blood test has been approved by the FDA for CRC screening in adults aged 45 years and older who are at average risk for the disease.
Pembrolizumab Plus Enfortumab Vedotin Earns CHMP Recommendation in Frontline Metastatic Urothelial Carcinoma
The CHMP has recommended pembrolizumab plus enfortumab vedotin-ejfv in frontline unresectable or metastatic urothelial carcinoma.
Fecal Microbiota Transplants May Enhance Immunotherapy Efficacy in GI Cancers
Donor fecal microbiota transplants increased the activity of immunotherapy in patients with GI cancers.
Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL
Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.
Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer
Shubham Pant, MD, MBBS, discusses findings from the phase 2b HERIZON-BTC-01 study of zanidatamab in pretreated HER2-positive biliary tract cancer.
FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer
The FDA has accepted the new drug application for the new TLX007-CDx cold kit for the preparation of PSMA-PET imaging in patients with prostate cancer.
Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL
The incidence of ICANS and CRS post-CAR T-cell therapy decreased after 2 weeks in patients with DLBCL, supporting a reduction of the monitoring period.
Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer
An EHR-based prompt or “nudge” decreased the rates of sentinel lymph node biopsy among older patients with early-stage breast cancer.
DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment
Paolo Tarantino MD, and V. K. Gadi, MD, PhD discuss data from DESTINY-Breast03 and DESTINY-Breast06.
V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76
V. Craig Jordan, PhD, of The University of Texas MD Anderson Cancer Center and a pioneer in the field of breast cancer, died on June 9, 2024.
340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences
Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.
EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC
The type II variation application for frontline nivolumab plus ipilimumab in unresectable/advanced hepatocellular carcinoma was validated by the EMA.
Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors
Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer